Impact of Selection of Cord Blood Units from the United States and Swiss Registries on the Cost of Banking Operations
Open Access
- 7 January 2013
- journal article
- research article
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 40 (1), 14-20
- https://doi.org/10.1159/000345690
Abstract
Background: Over the last 2 decades, cord blood (CB) has become an important source of blood stem cells. Clinical experience has shown that CB is a viable source for blood stem cells in the field of unrelated hematopoietic blood stem cell transplantation. Methods: Studies of CB units (CBUs) stored and ordered from the US (National Marrow Donor Program (NMDP) and Swiss (Swiss Blood Stem Cells (SBSC)) CB registries were conducted to assess whether these CBUs met the needs of transplantation patients, as evidenced by units being selected for transplantation. These data were compared to international banking and selection data (Bone Marrow Donors Worldwide (BMDW), World Marrow Donor Association (WMDA)). Further analysis was conducted on whether current CB banking practices were economically viable given the units being selected from the registries for transplant. It should be mentioned that our analysis focused on usage, deliberately omitting any information about clinical outcomes of CB transplantation. Results: A disproportionate number of units with high total nucleated cell (TNC) counts are selected, compared to the distribution of units by TNC available. Therefore, the decision to use a low threshold for banking purposes cannot be supported by economic analysis and may limit the economic viability of future public CB banking. Conclusions: We suggest significantly raising the TNC level used to determine a bankable unit. A level of 125 × 107 TNCs, maybe even 150 × 107 TNCs, might be a viable banking threshold. This would improve the return on inventory investments while meeting transplantation needs based on current selection criteria.Keywords
This publication has 16 references indexed in Scilit:
- Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseasesBest Practice & Research Clinical Haematology, 2010
- The Mannheim Cord Blood Bank: Experiences and Perspectives for the FutureTransfusion Medicine and Hemotherapy, 2010
- Costs of pediatric allogeneic hematopoietic‐cell transplantationPediatric Blood & Cancer, 2009
- Problems in Umbilical Cord Blood CollectionTransfusion Medicine and Hemotherapy, 2007
- Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking programTransfusion, 2005
- Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT)Transplantation and Cellular Therapy, 2005
- History of the clinical use of umbilical cord blood hematopoietic cellsCytotherapy, 2005
- Reasons for discard of umbilical cord blood units before cryopreservationTransfusion, 2000
- Haematopoietic Transplant Potential of Unrelated and Related Cord Blood: The first six Years of the EUROCORD/NETCORD Bank GermanyKlinische Padiatrie, 1999
- Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.Proceedings of the National Academy of Sciences of the United States of America, 1995